A Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis

Healthcare Homoeo Charitable Society

Status and phase: Unknown; Phase 2

Conditions: Rheumatoid Arthritis.

Treatments: Drug: Rhustoxicodendron 30; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01905735

SLSGB-01

Details and patient eligibility

About

the purpose of the study is to assess the safety and efficacy of commonly used Homeopathic medicine Rhustoxicodendron in 30 potency in the treatment of Rheumatoid arthritis.

Full description

it is a multicenter phase 2 ,double blind study in patient with active Rheumatoid arthritis ,there are 2 group in the study A and B ,where group A receive Rhustoxicodendron in 30 potency the first dose will administered orally (1/2 ml)after the completion of case taking ,and repeated every 7th day for 5 month and on the other hand group B receive placebo orally in (1/2 ml) at same interval for same period .

Enrollment: 60 estimated patients

Sex: All

Ages: 25 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• those who will provide written consent to participate in the study
• patient willing to turn up for 7th day follow up
• patient who are willing and compliance to the study
• those who are between 25 to 60 years .
• patient who are willing and compliance to the study .
• ESR more then 28 mm.

Exclusion criteria

• Participating as a subject in any other clinical research study.
• Children below the age of 25years.
• Female subject who are pregnant or planning for pregnancy within 6 month.
• History of seizures
• Breast feeding women's.
• Patient on treatment for life threatening illness like cancer aids etc.
• Patient should not have any congenital abnormality or patient should not have undergone any operative procedure as consequences of RA.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups, including a placebo group

placebo

Placebo Comparator group

Description:

1/2 ml of dispensing alcohol administered orally at every 7 day for 5 month .

Treatment:

Drug: placebo

Rhustoxicodendron 30

Active Comparator group

Description:

1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.

Treatment:

Drug: Rhustoxicodendron 30